Brief: Black Diamond Therapeutics Announces Preliminary Phase 2 Data For Silevertinib In 1L Nsclc
03/12/2025 13:04
Dec 3 (Reuters) - Black Diamond Therapeutics Inc BDTX.O: BLACK DIAMOND THERAPEUTICS ANNOUNCES PRELIMINARY PHASE 2 DATA FOR SILEVERTINIB IN 1L NSCLC AND PLANS FOR A PHASE 2 TRIAL OF SILEVERTINIB IN GBM BLACK DIAMOND THERAPEUTICS INC - SILEVERTINIB SHOWS 60% ORR AND 86% CNS RESPONSE IN 1L NSCLC BLACK DIAMOND THERAPEUTICS INC: PFS DATA FOR 1L NSCLC PATIENTS EXPECTED IN Q2 2026 BLACK DIAMOND: TO INITIATE RANDOMIZED PHASE 2 TRIAL OF SILEVERTINIB IN NEWLY DIAGNOSED GBM PATIENTS IN 1H 2026; INITIAL DATA ANTICIPATED IN 2028 Source text: ID:nGNX9QdPWj Further company coverage: BDTX.O ((Reuters.Briefs@thomsonreuters.com;))